PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Shin Poong Pharmaceutical returned to full-year profit in 2025 after four years of losses, but swung back into a large quarterly loss in Q2 2026 amid a dual challenge of sales-force outsourcing and generic drug price cuts.
The company posted consolidated operating profit of roughly KRW 14.3 billion and owners' net income of about KRW 8.8 billion in 2025, its first annual profit in four years.
Q2 2026 revenue of about KRW 63.9 billion was the highest in the last five quarters, yet operating and net losses each reversed to roughly KRW 8 billion.
The company has shifted its entire domestic sales organization, except the general-hospital division, to a contract sales organization (CSO) model.
A government policy lowering the generic drug pricing formula is a swing factor for profitability given the company's reliance on prescription and generic sales.
Expanding exports of the antimalarial Pyramax and the second-half sales contribution from new products such as Hyalflex and Avosial are key items to watch.
Shin Poong Pharmaceutical's core business is prescription drugs centered on improved generics and generic products, while it also exports its self-developed antimalarial Pyramax through public procurement channels overseas.
Pyramax has been listed as a first-line treatment in several African countries and demand is being sustained there, with procurement volumes through the international body known as the Global Fund also increasing.
In the domestic market, cardiovascular combination drugs and generics form the revenue base, and the company has recently expanded its portfolio with new launches such as the benign prostatic hyperplasia treatment Avosial and the osteoarthritis injection Hyalflex.
The centerpiece of its new-drug pipeline is SP-8203 (otaplimastat), a first-in-class candidate for ischemic stroke that is currently in a large-scale global Phase 3 trial.
The company also carries several other candidates on its R&D list, including osteoarthritis and cardiovascular combination drugs, and has recently added animal medicine and animal medical device fields to its business scope to explore new growth areas.
Overseas operations run through local subsidiaries in Vietnam, the Philippines and Myanmar as well as a U.S. subsidiary, ShinPoong USA, which is headquartered in Irvine, California and wholly owned by the parent.
Domestically, the company converted its entire sales organization except the general-hospital division to a contract sales organization (CSO) model this year to lower fixed costs.
Within the competitive landscape it is classified as a mid-sized pharmaceutical company, and unlike larger peers it has notably pivoted toward greater reliance on outsourced sales rather than an in-house sales network.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩58.6B | ₩4.9B | 8.4% |
| 2025Q3 | ₩62.6B | ₩7.2B | 11.5% |
| 2025Q4 | ₩58B | ₩3.9B | 6.7% |
| 2026Q1 | ₩54.5B | -₩400M | −0.7% |
| 2026Q2 | ₩63.9B | -₩8B | −12.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩209.3B | -₩34B | -₩35.4B | −16.3% | −10.7% | 9.3% |
| 2023 | ₩200.2B | -₩47.4B | -₩57.3B | −23.7% | −21.3% | 29.3% |
| 2024 | ₩221.1B | -₩20.5B | -₩15.4B | −9.3% | −6.0% | 32.5% |
| 2025 | ₩234.7B | ₩14.3B | ₩8.8B | 6.1% | 3.3% | 30.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Consolidated revenue moved from about KRW 209.3 billion in 2022 to about KRW 200.2 billion in 2023, about KRW 221.1 billion in 2024 and about KRW 234.7 billion in 2025, dipping before rising again.
Operating profit was negative for three straight years from 2022 to 2024 — about -KRW 34.0 billion in 2022, about -KRW 47.4 billion in 2023 (operating margin -23.7%), and about -KRW 20.5 billion in 2024 — before turning to a profit of about KRW 14.3 billion in 2025 (operating margin 6.1%).
Owners' net income also turned positive at about KRW 8.8 billion in 2025, a reversal from large losses of roughly -KRW 35.4 billion, -KRW 57.3 billion and -KRW 15.4 billion in 2022, 2023 and 2024 respectively.
On a quarterly basis, Q3 2025 (revenue about KRW 62.6 billion, operating profit about KRW 7.2 billion, net income about KRW 6.4 billion) was the strongest in the recent window, and the profitable trend continued into Q4 2025 (revenue about KRW 58.0 billion, operating profit about KRW 3.9 billion, net income about KRW 0.5 billion).
Q1 2026 saw revenue of about KRW 54.5 billion with a small operating loss of about KRW 0.4 billion, though net income stayed slightly positive at about KRW 0.4 billion.
Then in Q2 2026, revenue rose to about KRW 63.9 billion, the highest of the last five quarters, yet the company posted an operating loss of about KRW 8.0 billion and a net loss of about KRW 8.0 billion, swinging back into a substantial deficit.
The sharp deterioration despite higher revenue is attributed to costs tied to the CSO transition — including severance payments for the sales force and a period of dual cost burden alongside new commission expenses — with reporting noting that Q1 severance expense alone rose about 70% year over year.
Management has said that revenue tied to the CSO shift is expected to materialize mainly from the third and fourth quarters, making it a key point to watch whether second-half earnings can offset these transition costs.
The domestic pharmaceutical industry is under pressure as the government pushes to lower the generic drug pricing formula from the existing 53.55% of the originator price to the low-40% range, squeezing profitability at mid-sized companies with high exposure to prescription and generic sales.
Industry observers have raised concerns that companies with heavier reliance on contract sales organizations (CSOs) will feel a greater impact from this policy shift.
Against this backdrop, several mid-sized drugmakers including Shin Poong, Boryung and JW Choongwae have been increasing their use of CSOs instead of in-house sales forces.
Conversely, in the overseas antimalarial market, demand has stayed firm as Shin Poong's Pyramax is listed as a first-line treatment in major African countries and procurement volumes through the international Global Fund continue to rise.
In the domestic prescription market, price cuts and simplified generic substitution rules are advancing simultaneously, reshaping the generic distribution structure itself, with related variables such as CSO commission negotiations and a government fact-finding review of the CSO sector also in play.
At its 2026 New Year kickoff event, the company laid out new-product-driven revenue growth, domestic and overseas market development, production facility investment, and systematic pipeline management as its key priorities.
To that end, it plans to invest more than KRW 60 billion over the next three years in a new injectable production line at its Osong plant and automation equipment at its Ansan plant.
Among new products, the osteoarthritis injection Hyalflex began contributing some revenue from the second quarter, and management expects a fuller sales contribution in the second half.
Pyramax sales rose from about KRW 4.8 billion in 2023 to about KRW 10.2 billion in 2024 and about KRW 13.7 billion in 2025, and grew sharply again in Q1 2026 to about KRW 5.6 billion versus about KRW 1.6 billion a year earlier, leading the company to expect full-year Pyramax sales to exceed the prior year.
The stroke drug candidate SP-8203 is in a multicenter, randomized global Phase 3 trial enrolling 852 patients, with no officially confirmed completion date yet.
Management has also said that Phase 3 clinical results for Pyramax's COVID-19 indication are being prepared for publication in an international journal, targeting early next year.
In addition, Pyramax's listing as a domestic malaria treatment in the malaria treatment guideline revised by the Korea Disease Control and Prevention Agency in March 2026 could support broader domestic prescribing.
Shin Poong Pharmaceutical sustained profitability into Q1 2026 after turning profitable for the full year 2025, but the swing back to a large loss in Q2 means quarterly earnings volatility remains a key consideration for valuation.
On a trailing four-quarter basis (Q3 2025 through Q2 2026), owners' net income sums to a modest loss, indicating that the annual profit recovery has not yet translated into stable quarterly results.
The price-to-book ratio has traded at a level that carries a premium over net asset value, and the market's focus appears to be shifting away from the valuation dynamics once driven by COVID-19 treatment expectations toward operating fundamentals such as operating margin and the sales contribution of new products.
On the dividend front, payout history has been limited in recent years, so the sustainability of the profit turnaround and the timing of when one-off CSO transition costs fade out remain the central variables for assessment rather than dividend appeal.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
The company achieved its first annual profit in four years in 2025, with operating profit of about KRW 14.3 billion and owners' net income of about KRW 8.8 billion. The SG&A-to-sales ratio fell sharply over two years, reflecting genuine cost-structure efficiency gains.
Both revenue growth and cost reduction contributed, marking a tangible result of the company's restructuring efforts.
New products such as the BPH treatment Avosial and the osteoarthritis injection Hyalflex have been launched in sequence, with sales contributions expected in the second half.
The antimalarial Pyramax continues to grow in sales each year as it gains first-line listings in Africa and expands procurement through the Global Fund. Growth in both new products and exports has the potential to partially offset the impact of domestic price cuts.
The first-in-class stroke drug candidate SP-8203 has entered a global Phase 3 trial enrolling 852 patients. The company is also broadening its R&D portfolio into new areas such as animal medicines and animal medical devices. Should the pipeline advance toward commercialization, it could become a new growth driver.
Q2 2026 revenue hit a quarterly high, yet operating and net losses each widened to roughly KRW 8 billion. This illustrates the instability of a profit structure where revenue growth does not immediately translate into earnings. Such volatility reduces the predictability of quarterly results.
As the government pushes to lower the generic pricing formula from 53.55% of the originator price to the low-40% range, margin pressure is a concern for companies with high exposure to prescription and generic sales. The magnitude of the impact will depend on the specific timing and scale of implementation. This is a structural variable affecting the industry broadly.
One-off costs such as severance payments increased during the process of shifting the entire clinic-level sales organization to CSOs. With commission rate negotiations and a government fact-finding review of the CSO sector overlapping, the benefits of the transition could take longer than expected to materialize. The risk of a sales gap during the early transition period cannot be ruled out either.
Discussions on generic price cuts and improving CSO distribution structures are proceeding simultaneously, so the revenue and commission structure could change substantially depending on the specific timing and scope of implementation.
The government has signaled plans to run a public-private council addressing both generic activation and CSO reform. Policy uncertainty could persist for a considerable period.
Given that Pyramax's earlier Phase 3 trial for a COVID-19 indication ended in failure, uncertainty remains for pipeline candidates such as the ongoing SP-8203 Phase 3 trial until final results are confirmed. Large multicenter trials can also face variables in patient recruitment and timeline management. A clinical failure would also lower the likelihood of recovering related R&D investment.
As seen in the swing from a small operating profit in Q1 2026 to a large operating loss in Q2, quarterly earnings predictability can decline in periods when one-off costs and early-stage new-product expenses overlap.
If revenue growth does not consistently translate into earnings improvement, rebuilding market confidence could take time.
Check the Q3 2026 (July-September) quarterly report for whether CSO-related revenue materializes and how the generic price cuts actually affect earnings.
This is the point to check whether new products such as Hyalflex and Avosial begin contributing meaningfully to sales, and whether full-year Pyramax sales exceed the prior year.
Watch for whether Phase 3 clinical results for Pyramax's COVID-19 indication are published in an international journal as planned.
Continue to monitor the progress and eventual results timeline of the 852-patient global Phase 3 trial for the stroke drug candidate SP-8203.
Shin Poong Pharmaceutical achieved a full-year return to profit in 2025, but Q2 2026 saw quarterly earnings volatility resurface as operating and net losses each widened to roughly KRW 8 billion even as revenue hit a quarterly high.
The widened loss is attributed to a combination of one-off costs from the CSO transition, including severance payments, and early-stage marketing expenses for new products, with the company expecting CSO-related revenue and new-product contributions to build mainly in the second half.
At the same time, the government's policy to lower the generic drug pricing formula could pose a structural burden across companies with high exposure to prescription and generic sales.
On the other hand, expanding overseas public procurement of the antimalarial Pyramax and the ongoing Phase 3 trial for the stroke drug candidate SP-8203 are cited as medium- to long-term growth drivers.
Ultimately, the timing of when one-off CSO transition costs fade and the actual pace at which new-product and export revenue materialize will be key variables in gauging how quickly earnings can recover.
Investors will want to watch upcoming quarterly reports to see whether the real effects of this structural transition show up in the numbers.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.